Kenvue stock holds near $18.70 after August earnings miss

Published on 09/07/2026 at 17:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Kenvue stock trades near $18.70 after the August 6 earnings report showed $0.31 EPS and $3.96 billion in revenue.

Isometrische 3D-Illustration einer Konsumgüter-Lieferkette mit Fabrik und Lager — Isometrisches 3D-Diagramm der Wertschöpfungskette illustriert Produktion und Vertrieb von Kenvue ISIN US49177J1025, Illustration mit AI erstellt.

Kenvue Inc. stock (US49177J1025) traded at $18.70 after the August 6 earnings update, with a market cap of $35.92 billion and a 52-week range of $14.02 to $20.69. The same report showed $0.31 earnings per share on revenue of $3.96 billion, while MarketBeat said that the quarter missed the $0.32 EPS consensus by $0.01.

Earnings set the tone

The latest quarter was a clear comparison point: revenue rose 3.0 percent year over year from the same period last year, and net margin reached 10.76 percent. MarketBeat also put current-year EPS expectations at $1.14, which gives investors a simple yardstick for the rest of 2026.

The dividend added another dated marker. Kenvue paid a quarterly dividend of $0.21 per share on August 26, after an August 12 ex-dividend date, which implies an annualized payout of $0.84 and a yield of 4.5 percent.

What investors watch

The stock price of $18.70 sits below the 52-week high of $20.69 and above the low of $14.02, so the chart is still trading inside a wide range. For now, the key test is whether Kenvue can turn the August 6 quarter's 3.0 percent revenue growth into a cleaner earnings beat.

Skin and household brands

Kenvue's consumer-health portfolio includes brands such as Tylenol, Neutrogena and Listerine, and that mix still matters because the group depends on steady repeat demand rather than big one-off orders. The August quarter's 10.76 percent net margin shows why scale and pricing power remain central for the stock.

Price and market view

As of September 7, 2026, the shares were quoted at $18.70 on NYSE, with a market capitalization of $35.92 billion. That leaves Kenvue stock in the middle of its annual trading band rather than at a fresh high or low.